Table 2.
Studies on awake ECMO in COPD and ARDS patients
Reference | Year | Type of disease | Number of patients | Average support duration (days) | Type of extracorporeal support | Successful management without IMV | Successful weaning from IMV |
---|---|---|---|---|---|---|---|
Kluge et al. [68] | 2012 | COPD | 14 | 9 | PECLA | 13/14 | NA |
Burki et al. [66] | 2013 | COPD | 20 | 4 | Low flow ECCO2R | 9/9* | 3/11§ |
Abrams et al. [65] | 2013 | COPD | 5 | 8 | Low flow ECCO2R | NA | 5 |
Del Sorbo et al. [67] | 2015 | COPD | 25 | 2 | Low flow ECCO2R | 22/25 | NA |
Hoeper et al. [70] | 2013 | ARDS | 6 | 10 | VV | 3/6 | NA |
Studies on awake ECMO for acute exacerbation of COPD or ARDS reporting at least five patients are presented in chronological order of publication and according to type of disease. “Successful management without IMV” defines the number of patients managed without invasive mechanical ventilation during the ICU stay. “Successful weaning from IMV” defines the number of patients already intubated, mechanically ventilated, and on ECMO who were weaned from invasive mechanical ventilation, extubated, and managed with awake ECMO. *Patients of groups 1 and 2 and §patients of group 3 of the original publication by Burki et al.
ARDS acute respiratory distress syndrome, COPD chronic obstructive pulmonary disease, ECCO 2 R extra-corporeal CO2 removal, IMV invasive mechanical ventilation, NA not available, PECLA pumpless extra-corporal lung assist; VV veno-venous